Notice of annual general meeting in Biovitrum AB (publ), April 24,
2008
The shareholders in Biovitrum AB (publ), Reg. No. 556038-9321, are
hereby summoned to the annual general meeting (the "Meeting"), to be
held on Thursday 24 April 2008 at 4.00 p.m. at Berns Salonger,
Berzelii Park, Stockholm, Sweden.
Participation, etc
Shareholders who wish to attend the Meeting must be recorded in the
share register maintained by VPC AB (the Swedish Central Securities
Depository) on Friday 18 April 2008, and must notify the company of
their intention to participate in the Meeting not later than 4.00
p.m. on Friday 18 April 2008 at Biovitrum's web site
www.biovitrum.com, by mail to Biovitrum AB (publ), "Annual General
Meeting", 112 76 Stockholm, Sweden or by phone no. +46 8 697 34 27.
The notification shall set forth the name, address, telephone number
(daytime), personal/corporate identity number, the number of shares
held and, when applicable, information about representatives and
assistants. Per the day of this notice there are 45,622,700 shares
and votes outstanding in the company.
Nominee shares
Shareholders, whose shares have been registered in the name of a
nominee through the trust department of a bank or similar
institution, must temporarily re-register their shares in their own
names in the shareholders' register maintained by VPC AB to be
entitled to participate in the Meeting. Shareholders must inform
their nominee of such re-registration well before Friday 18 April
2008, when such re-registration must have been executed.
Proxy, etc
Shareholders represented by proxy shall issue a written and dated
power of attorney for the proxy. If the power of attorney is issued
on behalf of a legal entity, a certified copy of a registration
certificate for the legal entity shall be appended. The power of
attorney and the registration certificate may not be older than one
year. The power of attorney in original and, when applicable, the
registration certificate, should be submitted to the company by mail
at the address indicated above well before the Meeting. A proxy form
is held available at the company's web site, www.biovitrum.com, and
will also be sent to shareholders who so request and who inform the
company of their postal address.
Attachment: Notice of annual general meeting in Biovitrum AB (publ)
2008.
For more information, please contact:
Biovitrum AB (publ)
Martin Nicklasson,
CEO
Phone: +46 8 697 20 00
martin.nicklasson@biovitrum.com
About Biovitrum
Biovitrum is a pharmaceutical company with operations in Sweden and
in the UK. Biovitrum has currently a research portfolio with several
projects in clinical and preclinical phases for a number of well
defined specialist indications as well as for common diseases within
obesity, diabetes, inflammation and eye diseases. Biovitrum develops
and produces protein-based drugs on a contractual basis and markets a
range of specialist pharmaceuticals primarily in the Nordic
countries. Biovitrum has revenues of approximately SEK 1.2 billion
and around 500 employees. Biovitrum's share is listed on the OMX
Nordic Exchange in Stockholm since September 15, 2006. For more
information see www.biovitrum.com.